stockrow
Friday 6 November 2026
Export RYTM’s income statement to Excel — free account
Rhythm Pharmaceuticals, Inc.
RYTM Healthcare Biotechnology
Rhythm Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $189.8 million, up 45.8% from fiscal 2024.
- Revenue
- +79.6%
- EPS
- +26.9%
- Free cash flow
- +95.4%
Quarter to September 2026, against a year earlier
112.38
7.36
+7.01%
Follow RYTM
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
36.66 | 27.22 | 31.74 | 23.42 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(273.97) | (133.79) | (832.15) | (2,147.15) | |
P/B ratio |
50.02 | 48.10 | 73.95 | 74.74 | |
Price to Tangible BV |
52.01 | 50.18 | 77.64 | 92.23 | |
EV/Sales |
34.61 | 25.65 | 30.36 | 22.27 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(56.77) | (46.62) | (69.15) | (76.46) | |
EV/FCF |
(40.76) | (33.77) | (48.31) | (49.15) | |
Quick Ratio |
3.92 | 3.63 | 3.00 | 2.39 | |
Current Ratio |
4.41 | 4.17 | 3.45 | 2.78 | |
Net Debt/EBITDA |
8.31 | 6.54 | 6.85 | 8.22 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.44 | 0.52 | 0.59 | 0.59 | |
Operating CF/Net income |
0.52 | 0.78 | 0.18 | 0.07 | |
Capex/Depreciation |
(3.50) | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
(10.20) | (11.42) | (10.69) | (8.74) | |
Research and Development Expense of Revenue |
73.41% | 69.41% | 60.95% | 56.96% | |
Selling, General and Administrative Expense of Revenue |
100.40% | 105.79% | 94.66% | 72.46% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.04 | |
Share Based Compensation of Revenue |
33.65% | 38.43% | 36.57% | 27.16% | |
Graham Net Nets |
0.04 | 0.04 | 0.03 | 0.03 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(2.91%) | (3.60%) | (2.80%) | (3.03%) | |
Free Cash Flow Yield |
(2.32%) | (2.79%) | (1.98%) | (1.94%) | |
Revenue per Share |
0.88 | 0.88 | 1.04 | 1.33 | |
Operating CF per Share |
(0.39) | (0.65) | (0.13) | (0.04) | |
Capex per Share |
(0.01) | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.41) | (0.65) | (0.13) | (0.04) | |
Cash per Share |
5.99 | 5.01 | 4.82 | 4.65 | |
Shareholders Equity per Share |
4.16 | 3.50 | 3.17 | 2.92 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.16 | 3.50 | 3.17 | 2.92 | |
Free Cash Flow |
(26.34) | (44.18) | (9.15) | (3.06) | |
Working Capital |
360.97 | 326.89 | 302.98 | 268.47 | |
Capital Expenditures |
(0.95) | — | — | — | |
Net Current Asset Value |
256.75 | 225.39 | 206.60 | 177.77 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
22.30 | 26.01 | 33.27 | 36.08 | |
Average Payables |
13.14 | 12.11 | 16.07 | 12.16 | |
Average Inventory |
22.25 | 23.98 | 24.69 | 26.65 | |
Average Assets |
436.23 | 414.50 | 405.00 | 475.00 | |
Average Common Equity |
80.40 | 70.93 | 45.54 | 118.39 |
Columns are period end dates · fundamentals updated 5 Nov 2026